导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.06% | 1446/4773 |
| 近一周 | -1.86% | 803/5462 |
| 近一月 | -2.84% | 1429/5421 |
| 近一季 | -5.27% | 1798/5209 |
| 近半年 | -0.30% | 1262/4920 |
| 近一年 | 8.68% | 1163/4366 |
| 近两年 | 52.47% | 1409/2954 |
| 近三年 | 38.46% | 760/2253 |
| 成立以来 | 50.84% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.56% 1847/4961 |
11.28% 2351/5312 |
- - |
- - |
| 2025 | 22.51% 1965/4813 |
0.99% 1721/3635 |
1.65% 2241/4076 |
15.07% 2846/4524 |
3.70% 642/4813 |
| 2024 | 17.56% 677/3463 |
5.98% 323/2808 |
-0.11% 682/3014 |
12.73% 2298/3129 |
-1.49% 1724/3463 |
| 2023 | -9.25% 1140/2656 |
3.34% 1215/2280 |
-3.31% 769/2385 |
-2.64% 710/2515 |
-6.71% 1886/2655 |
| 2022 | -24.32% 1207/2207 |
-13.38% 748/1919 |
4.41% 1015/2016 |
-13.68% 946/2113 |
-3.06% 1831/2208 |
| 2021 | -1.05% 776/1822 |
-4.00% 842/1255 |
6.48% 744/1330 |
-4.53% 717/1466 |
1.40% 944/1822 |
| 2020 | - - |
- - |
- - |
18.14% 87/1164 |
13.60% 347/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方沪深300增强A VS. 长安沪深300非周期A(740101) |